- Report
- August 2025
- 192 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 280 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 276 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- July 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- June 2025
- 200 Pages
Global
From €2443EUR$2,789USD£2,120GBP
- Report
- July 2025
- 140 Pages
Global
From €4248EUR$4,850USD£3,687GBP
- Report
- March 2022
- 300 Pages
Global
From €4379EUR$5,000USD£3,801GBP
Misoprostol is a synthetic prostaglandin E1 analog used in the treatment of gastrointestinal disorders. It is used to reduce the risk of stomach ulcers in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). It is also used to induce labor, treat postpartum hemorrhage, and induce abortion. It is available in both oral and rectal forms.
Misoprostol is a widely used drug in the gastrointestinal drug market. It is used to reduce the risk of stomach ulcers in patients taking NSAIDs, as well as to induce labor, treat postpartum hemorrhage, and induce abortion. It is also used to treat other gastrointestinal disorders, such as gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease.
Some companies in the Misoprostol market include Pfizer, Merck, GlaxoSmithKline, Novartis, and Sanofi. Show Less Read more
